Effect of Consuming Products Containing Rare Sugars Alongside Sucrose on Glycaemic Response in Healthy Adults

April 25, 2022 updated by: University of Nottingham

Food manufacturers are being tasked to reduce the added sugar content of products. Rare, but natural sugars, may serve as useful sweeteners as they are low-calorie, safe, sweet and have a mild taste. Previous studies have shown that consuming rare sugars alongside other carbohydrates leads to a lower spike in blood glucose after eating. This means that products containing rare sugars may provide health benefits. However, most studies use rare sugars in a glucose drink, so the effect of consuming rare sugars in foods is not known.

The aim of this study is to find out whether consuming sweet crème products containing rare sugars reduces the blood glucose response compared to sucrose-only products. The effect of the rare sugar products on hunger and appetite will also be assessed.

Participants will attend the Clinical Research Facility on 6 occasions, after fasting for 10 hours. At each visit, they will consume a different sample of sweet crème. They will be asked to give blood samples before eating the sample, and at regular intervals for 2 hours afterwards. They will also complete questionnaires to assess their appetite using linear scales. Blood samples will be analysed in the laboratory to measure the level of glucose and insulin at each time point. The changes in blood glucose and insulin after consuming the different samples will be compared to find out if the samples containing rare sugars reduced the response.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Main Hypotheses:

This study is designed to test two main hypotheses:

  1. Sweet crème products containing the rare sugars arabinose or tagatose will cause a lower spike in blood glucose and insulin than sucrose-only products.
  2. Sweet crème products containing the rare sugars arabinose or tagatose will be no less satiating than sucrose-only products.

The null hypotheses are therefore:

  1. Levels of blood glucose and insulin are not significantly different after consuming sweet crème products containing rare sugars compared to sucrose-only products.
  2. Appetite and food intake are significantly higher after consuming sweet crème products containing rare sugars compared to sucrose-only products.

Study Overview:

This study will be a double-blind crossover trial, allowing each participant to act as their own control. Twenty participants will be recruited and fully informed about the study before giving informed consent. Eligible participants will attend the Clinical Research Facility on 6 separate mornings following an overnight fast. On each occasion participants will consume 40-50g of sweet crème served with commercially available sweet wafers. Sweet crème samples will contain vegetable fat and sucrose with or without the addition of D-tagatose or L-arabinose. Neither the participants or the researchers administering the tests will be aware of which sample is being consumed at each visit. Blood samples will be taken before consumption and at regular intervals for 120 minutes afterwards. Blood samples will be analysed to measure plasma glucose, insulin, and the appetite-regulating hormones GLP-1 and GIP. During each visit participants will also be asked to complete questionnaires assessing their hunger and desire to eat, and any gastrointestinal symptoms.

Samples:

Six different sweet crème samples will be included as listed below:

SUC- Full-sucrose sample (2.5:1 sucrose:vegetable fat)

CONTROL- Reduced-sucrose sample (1.5:1 sucrose:fat)

ARA20- Low-dose arabinose sample (1.5:1:0.5 sucrose:fat:arabinose)

ARA40- High-dose arabinose sample (1.5:1:1 sucrose:fat:arabinose)

TAG20- Low-dose tagatose sample (1.5:1:0.5 sucrose:fat:tagatose)

TAG40- High-dose tagatose sample (1.5:1:1 sucrose:fat:tagatose)

Using these samples, we will be able to investigate the effect of adding rare sugars to a constant sucrose/fat load (by comparing each experimental product with the control product), and also to investigate the effect of replacing sucrose with rare sugars (by comparing ARA40 and TAG40 products with the SUC product).

Study visits:

Each participant will visit on 6 occasions and consume one of the six samples on each visit in a randomised order.

Visits will be separated by at least one week, so each participant is expected to be involved in the study for 2-3 months from start to finish. A randomised crossover design has been selected so that each participant can act as their own control, which reduces the impact of variation in glycaemic response between individuals. The crossover design will therefore allow us to detect significant differences with a smaller number of participants.

At each clinic visit we will measure the glycaemic response (increase in blood glucose and insulin), using methods similar to the standard methodology for assessing glycaemic index. We will also evaluate the effect of the samples on hunger and desire to eat, and gastrointestinal symptoms, using adapted validated questionnaires.

The procedures for each clinic visit are summarised below:

  1. Pre-visit fast:

    Participants will fast for 10 hours before visit. All visits will be scheduled before 10am.

  2. Clinic visits:

    Participants will visit the clinic on 6 occasions, separated by at least one week. Each visit will last around 3 hours. Every effort will be made to ensure participants are comfortable during clinic visits. Participants will be seated comfortably throughout, and will be asked to remain seated as much as possible. They will be allowed to read or use laptops/phones, and toilet visits will be permitted.

  3. Health questionnaire:

    An initial health questionnaire will ask for details of BMI, smoking, alcohol consumption, habitual exercise and gastrointestinal symptoms. Questionnaires on subsequent visits will assess gastrointestinal symptoms only.

  4. Blood sampling:

    Research nurses at the CRF will insert cannula in a vein in the hand. Blood will be sampled at baseline and at 15, 30, 45, 60, 90 and 120 minutes after consumption of the sample.

  5. Consumption of product and sensory question:

    Researchers will ask participants to consume a sample consisting of 40-50g sweet crème served with commercially available wafers. They will be asked to rate their liking of the product on a 9-point hedonic scale.

    The quantity and composition of the samples has been carefully considered to ensure that they will cause a sufficient glycaemic response for us to be able to detect significant differences between samples. The composition is similar to typical sweet crème products (eg the centre of an Oreo biscuit), and it will be served with ice cream wafers to increase the palatability for participants. Participants will be asked to rate their liking of each sample immediately after consuming it using a hedonic scale.

    Neither the participant nor the researcher administering the clinic visit will be aware of which sample is being consumed at each visit.

  6. Appetite questionnaires:

    Researchers will administer paper-based questionnaires using visual analogue scores to ask participants how hungry/full they feel and their desire to eat certain foods. In order to capture changes in appetite over the clinic visit, participants will be asked to complete the same questionnaire at baseline and at 35, 65 and 125 minutes after consuming the product.

  7. Buffet meal:

    After the 120 minute blood sampling, cannulas will be removed and participants will be offered a buffet meal consisting of a range of sweet and savoury foods, served with water. Researchers will record the food intake of each participant.

  8. 24 hour food diary: Participants will be asked to record their food intake for the rest of the day (until midnight on the day of the study visit) on a paper-based food diary.

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy adults of any gender and any sociodemographic background, who are capable of giving informed consent.
  • Aged 18 years or over (no upper age limit).
  • Able to understand spoken and written English well enough to understand the consent forms and information sheets, and to give responses to questionnaires.

Exclusion Criteria:

  • Diagnosed hyperglycaemia, insulin resistance, diabetes or high blood pressure.
  • Allergy, intolerance, sensitivity or dietary restriction that would prevent the consumption of the sweet crème samples.
  • Anxiety/phobias that would prevent the sampling of venous blood.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group T: ABCDEF
Participants will receive all six blind-coded samples, in the order A, B, C, D, E, F. There will be a minimum of 7 days washout between samples.
Other: SUCROSE
50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
Other: CONTROL
35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
Other: ARA20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
Other: ARA40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Other: TAG20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
Other: TAG40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Experimental: Group V: FABCDE
Participants will receive all six blind-coded samples, in the order F, A, B, C, D, E. There will be a minimum of 7 days washout between samples.
Other: SUCROSE
50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
Other: CONTROL
35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
Other: ARA20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
Other: ARA40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Other: TAG20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
Other: TAG40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Experimental: Group W: EFABCD
Participants will receive all six blind-coded samples, in the order E, F, A, B, C, D. There will be a minimum of 7 days washout between samples.
Other: SUCROSE
50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
Other: CONTROL
35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
Other: ARA20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
Other: ARA40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Other: TAG20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
Other: TAG40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Experimental: Group X: DEFABC
Participants will receive all six blind-coded samples, in the order D, E, F, A, B, C. There will be a minimum of 7 days washout between samples.
Other: SUCROSE
50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
Other: CONTROL
35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
Other: ARA20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
Other: ARA40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Other: TAG20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
Other: TAG40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Experimental: Group Y: CDEFAB
Participants will receive all six blind-coded samples, in the order C, D, E, F, A, B. There will be a minimum of 7 days washout between samples.
Other: SUCROSE
50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
Other: CONTROL
35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
Other: ARA20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
Other: ARA40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Other: TAG20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
Other: TAG40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Experimental: Group Z: BCDEFA
Participants will receive all six blind-coded samples, in the order B, C, D, E, F, A. There will be a minimum of 7 days washout between samples.
Other: SUCROSE
50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
Other: CONTROL
35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
Other: ARA20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
Other: ARA40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
Other: TAG20
42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
Other: TAG40
50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Integrated area under the curve (iAUC) for plasma glucose.
Time Frame: 120 minutes
Differences in the iAUC for plasma glucose after consuming each product.
120 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak plasma glucose
Time Frame: 120 minutes
Differences in the peak value for plasma glucose after consuming each product.
120 minutes
Integrated area under the curve (iAUC) for plasma insulin.
Time Frame: 120 minutes.
Differences in the iAUC for plasma insulin after consuming each product.
120 minutes.
Peak plasma insulin
Time Frame: 120 minutes.
Differences in the peak value for plasma insulin after consuming each product.
120 minutes.
Integrated area under the curve (iAUC) and peak value for plasma GLP-1.
Time Frame: 120 minutes.
Differences in the iAUC and peak value for plasma GLP-1 after consuming each product.
120 minutes.
Integrated area under the curve (iAUC) and peak value for plasma GIP.
Time Frame: 120 minutes.
Differences in the iAUC and peak value for plasma GIP after consuming each product.
120 minutes.
Food intake at ad libitum buffet meal
Time Frame: 60 minutes
Total energy intake, macronutrient intake at ad libitum meal 120 minutes after product consumption.
60 minutes
24 hour food intake
Time Frame: 24 hours
Total energy intake, macronutrient intake until midnight after product consumption.
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Nottingham

Collaborators

Nottingham University Hospitals NHS Trust

Investigators

  • Principal Investigator: Preeti Jethwa, PhD, University of Nottingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

May 1, 2022

Primary Completion (Anticipated)

November 1, 2022

Study Completion (Anticipated)

November 1, 2022

Study Registration Dates

First Submitted

April 25, 2022

First Submitted That Met QC Criteria

April 25, 2022

First Posted (Actual)

April 29, 2022

Study Record Updates

Last Update Posted (Actual)

April 29, 2022

Last Update Submitted That Met QC Criteria

April 25, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 22013

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glycaemic Response in Healthy Participants

Clinical Trials on SUCROSE

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe